Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665192 · ClinicalTrials.gov registry record
A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 150
- Enrollment target
NCT05665192 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 150 participants.
The verdict
NCT05665192 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2023-07-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665192
The ClinicalTrials.gov registry entry for NCT05665192 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05665192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05665192 about?
NCT05665192 is a clinical study titled "A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib". The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.
What is the current status of trial NCT05665192?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2021-08-02. Estimated completion is 2023-07-24.
Who is sponsoring clinical trial NCT05665192?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.